Summary
The disposition of propranolol stereoisomers after administration of a single oral dose of the racemic drug was investigated in seven hyperthyroid patients before and after antithyroid drug therapy. The possibility of hypersensitivity to propranolol in the patients was evaluated by constructing plasma propranolol concentration — beta-blocking effect curves. There was no statistically significant difference in elimination half-life (t1/2) between (±)- and (−)-propranolol before and after antithyroid drug therapy. However, the plasma clearance (\(\dot V_p \)) of (−)-propranolol was smaller than that of (±)-propranolol, and the difference was statistically significant after antithyroid drug therapy. Decreased \(\dot V_p \) was observed in 3 aged hyperthyroid patients compared to the value after antithyroid drug therapy. \(\dot V_p \) decreased or did not change in young patients after therapy. No significant difference was observed in the relationship between the tilt-induced pulse rate response and plasma propranolol concentration when treated patients became euthyroid compared to their response in the hyperthyroid state.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aoki VS, Wilson WR, Theilen ED, Lukensmeyer WW, Leaverton PE (1967) The effects of triiodothyroine on hemodynamic responses to epinephrine and norepinephrine in man. J Pharmacol Exp Ther 157: 62–68
Bell JM, Russell CJ, Nelson JK, Kelly JG, McDevitt DG (1977) Studies of the effect of thyroid dysfunction on the elimination of β-adrenoceptor blocking drugs. Br J Clin Pharmacol 4: 79–82
Branch RA, Nies AS, Shand DG (1973) The disposition of propranolol VIII: General implications of the effects of the liver blood flow on elimination from the perfused rat liver. Drug Metab Dispos 1: 687–690
Branch RA, Shand DG, Wilkinson GR, Nies AS (1974) Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. J Clin Invest 53: 1101–1107
Breckenridge A (1971) Pathophysiological factors influencing drug kinetics. Acta Pharmacol Toxicol (Suppl 3) 29: 225–232
Brien JF, Inaba T, Kalow W (1975) Comparative drug elimination in man — diphenylhydantoin and amobarbital. Eur J Clin Pharmacol 9: 79–83
Cairoli VJ, Crout JR (1967) Role of the autonomic nervous system in the resting tachycardia of experimental hyperthyroidism. J Pharmacol Exp Ther 158: 55–65
Castleden CM, George CF (1979) The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 7: 49–54
Eichelbaum M, Bodem G, Gugler R, Schneider-Deters C, Dengler HJ (1974) Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med 290: 1040–1042
Feely J, Crooks J, Stevenson IH (1978) Alterations in plasma propranolol steady-state concentration in thyroid disease. Clin Pharmacol Ther 23: 112–113
George CF, Fenivesi T, Conolly ME, Dollery CT (1972) Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. Eur J Clin Pharmacol 4: 74–76
Grundin R, Moldéus P, Orrenius S, Borg KO, Skånberg I, von Bahr C (1974) The possible role of cytochrome P-450 in the liver “first pass elimination” of a β-receptor blocking drug. Acta Pharmacol Toxicol 35: 242–260
Hansen JM, Skovsted L, Kampmann JP, Lumholtz BL, Sierbaek-Nielsen K (1978) Unaltered metabolism of phenytoin in thyroid disorders. Acta Pharmacol Toxicol 42: 343–346
Hermansson J, von Bahr C (1980) Simultaneous determination of (d)-and (l)-propranolol in human plasma by high performance liquid chromatography. J Chromatogr 221: 109–117
Ishizaki T, Tawara K (1980) Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog. Br J Pharmacol (in press)
Kadar D, Inaba T, Endrenyi L, Johnson GE, Kalow W (1973) Comparative drug elimination capacity in man — glutethimide, amobarbital, antipyrine and sulfinpyrazone. Clin Pharmacol Ther 14: 552–560
Kalow W, Inaba T (1976) Genetic factors in hepatic drug oxidations. In: Popper H, Schaffner F (eds) Progress in liver diseases, vol. 5. Grune & Stratton, New York, pp 246–258
Kawashima K, Ishikawa H (1980) Pharmacokinetics of propranolol isomers and their relationships with β-adrenoceptor blocking activity administered with dl-propranolol. J Pharmacol Exp Ther 213: 628–631
Kawashima K, Levy A, Spector S (1976) Stereospecific radioimmunoassay for propranolol isomers. J Pharmacol Exp Ther 196: 517–523
Kelly JG, McDevitt DG (1978) Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism. Br J Clin Pharmacol 6: 123–127
Levy A, Ngai SH, Fink AD, Kawashima K, Spector S (1976) Disposition of propranolol isomers in mice. Eur J Pharmacol 40: 93–100
Mayers MG, Lewis PJ, Reid JL, Dollery CT (1974) Brain concentration of propranolol in relation to hypertensive effect in the rabbit with observations on brain propranolol levels in man. J Pharmacol Exp Ther 192: 327–335
McDevitt DG, Riddell JG, Hadden DR, Montgomery DAD (1978) Catecholamine sensitivity in hyperthyroidism and hypothyroidism. Br J Clin Pharmacol 6: 297–301
Meyers JD, Brannon ES, Holland BC (1950) A correlative study of the cardiac output and hepatic circulation in hyperthyroidism. J Clin Invest 29: 1069–1077
Nies AS, Evans GH, Shand DG (1973) The hemodynamic effects of beta-adrenergic blockade on the flow-dependent hepatic clearance of propranolol. J Pharmacol Exp Ther 184: 716–720
Nies AS, Shand DG, Wilkinson GR (1976) Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1: 135–155
Perrier, D, Gibaldi, M, Boyes RB (1973) Prediction of systemic availability from plasma level data after oral drug administration. J Pharm Pharmacol 25: 256–257
Perrier D, Gibaldi M (1974) Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther 191: 17–24
Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1: 123–136
Rumbaugh RC, Kramer RE, Colby HD (1978) Dose-dependent actions of thyroxine on hepatic drug metabolism in male and female rats. Biochem Pharmacol 27: 2027–2031
Saenger P, Rifkind AB, New MI (1976) Changes in drug metabolism in children with thyroid disorders. J Clin Endocrinol Metab 42: 155–159
Shand DG, Rangno RE (1972) The disposition of propranolol. Pharmacology 7: 159–168
Sjöqvist F, von Bahr C (1973) Interindividual differences in drug oxidation. Clinical importance. Drug Metab Dispos 1: 469–482
Vesell ES, Shapiro JR, Passananti GT, Jorgensen H, Shively CA (1974) Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther 17: 48–56
Vesell ES (1979) The antipyrine test in clinical pharmacology: Conceptions and misconceptions. Clin Pharmacol Ther 26: 275–287
Walle T, Walle UK (1979) Stereoselective oral bioavailability of (±)-propranolol in the dog. A GC-MS study using a stable isotope technique. Res Commun Chem Pathol Pharmacol 23: 453–464
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tawara, K., Kawashima, K., Ishikawa, H. et al. Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients. Eur J Clin Pharmacol 19, 197–203 (1981). https://doi.org/10.1007/BF00561949
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561949